Advertisement
Screener

Tenaya Therapeutics, Inc. (TNYA) Quick Ratio

2.8 / 5 stars · 68/120 Roast Me

Tenaya Therapeutics, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 4.12, a 27.17% decline year-over-year.
  • Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 5.45, a 12.46% decline year-over-year.
  • Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 6.51, a 69.35% increase year-over-year.
  • Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 4.26, a 13.22% decline year-over-year.
  • Tenaya Therapeutics, Inc. quick ratio for fiscal 2025 was 6.51, a 69.35% increase from fiscal 2024.
  • Tenaya Therapeutics, Inc. quick ratio for fiscal 2024 was 3.85, a 16.44% decline from fiscal 2023.
  • Tenaya Therapeutics, Inc. quick ratio for fiscal 2023 was 4.6, a 40.16% decline from fiscal 2022.
  • Tenaya Therapeutics, Inc. quick ratio for fiscal 2022 was 7.69, a 33.35% decline from fiscal 2021.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2026-06-304.12$78.46M$19.02M
2026-03-315.45$91.51M$16.78M
2025-12-316.51$100.55M$15.44M
2025-09-304.26$56.31M$13.21M
2025-06-305.66$71.67M$12.65M
2025-03-316.23$88.16M$14.15M
2024-12-313.85$61.45M$15.98M
2024-09-304.91$79.47M$16.18M
2024-06-305.94$99.3M$16.71M
2024-03-316.38$122.25M$19.16M
2023-12-314.6$104.64M$22.73M
2023-09-306.28$121.75M$19.38M
2023-06-306.33$132.51M$20.92M
2023-03-317.66$147.81M$19.31M
2022-12-317.69$186.53M$24.25M
2022-09-308.44$149.45M$17.72M
2022-06-309.65$180.92M$18.74M
2022-03-3111.02$210.45M$19.1M
2021-12-3111.54$251.3M$21.77M
2021-09-3020.48$280.47M$13.69M
2021-06-3011.42$111.89M$9.8M
2020-12-3125.5$128.54M$5.04M

Annual Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2025-12-316.51$100.55M$15.44M
2024-12-313.85$61.45M$15.98M
2023-12-314.6$104.64M$22.73M
2022-12-317.69$186.53M$24.25M
2021-12-3111.54$251.3M$21.77M
2020-12-3125.5$128.54M$5.04M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99